These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 9950667)
1. Vasoflux, a new anticoagulant with a novel mechanism of action. Weitz JI; Young E; Johnston M; Stafford AR; Fredenburgh JC; Hirsh J Circulation; 1999 Feb; 99(5):682-9. PubMed ID: 9950667 [TBL] [Abstract][Full Text] [Related]
2. Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist. Buchanan MR; Brister SJ Thromb Res; 2000 Sep; 99(6):603-12. PubMed ID: 10974347 [TBL] [Abstract][Full Text] [Related]
3. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790 [TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis). Peters RJ; Spickler W; Théroux P; White H; Gibson M; Molhoek PG; Anderson HV; Weitz JI; Hirsh J; Weaver WD Am Heart J; 2001 Aug; 142(2):237-43. PubMed ID: 11479461 [TBL] [Abstract][Full Text] [Related]
5. Enhancement of heparin cofactor II anticoagulant activity. Bauman SJ; Church FC J Biol Chem; 1999 Dec; 274(49):34556-65. PubMed ID: 10574918 [TBL] [Abstract][Full Text] [Related]
6. Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin. Liaw PC; Becker DL; Stafford AR; Fredenburgh JC; Weitz JI J Biol Chem; 2001 Jun; 276(24):20959-65. PubMed ID: 11294849 [TBL] [Abstract][Full Text] [Related]
7. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin. Nagase H; Enjyoji K; Minamiguchi K; Kitazato KT; Kitazato K; Saito H; Kato H Blood; 1995 Mar; 85(6):1527-34. PubMed ID: 7888673 [TBL] [Abstract][Full Text] [Related]
8. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of thrombin inhibition by heparin cofactor II and antithrombin in the presence of the ray (Raja radula) skin dermatan sulfate. Ben Mansour M; Dhahri M; Vénisse L; Jandrot-Perrus M; Chaubet F; Maaroufi RM Thromb Res; 2009 Apr; 123(6):902-8. PubMed ID: 19046760 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms for the anticoagulant effect of heparin and related polysaccharides. Ofosu FA Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155 [TBL] [Abstract][Full Text] [Related]
11. Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin. Holland CA; Henry AT; Whinna HC; Church FC FEBS Lett; 2000 Nov; 484(2):87-91. PubMed ID: 11068038 [TBL] [Abstract][Full Text] [Related]
12. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Ofosu FA; Modi GJ; Smith LM; Cerskus AL; Hirsh J; Blajchman MA Blood; 1984 Sep; 64(3):742-7. PubMed ID: 6235872 [TBL] [Abstract][Full Text] [Related]
13. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. Becker DL; Fredenburgh JC; Stafford AR; Weitz JI J Biol Chem; 1999 Mar; 274(10):6226-33. PubMed ID: 10037709 [TBL] [Abstract][Full Text] [Related]
14. Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques. Demir M; Iqbal O; Untch B; Hoppensteadt DA; Gaikwad BS; Fareed J Clin Appl Thromb Hemost; 2001 Jan; 7(1):38-43. PubMed ID: 11190903 [TBL] [Abstract][Full Text] [Related]
15. Future alternatives to heparin: low-molecular-weight heparin and hirudin. Donayre CE; Ouriel K; Rhee RY; Shortell CK J Vasc Surg; 1992 Apr; 15(4):675-82. PubMed ID: 1313932 [TBL] [Abstract][Full Text] [Related]
16. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Bates SM; Weitz JI Am J Cardiol; 1998 Oct; 82(8B):12P-18P. PubMed ID: 9809887 [TBL] [Abstract][Full Text] [Related]
17. Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate. Casu B; Guerrini M; Torri G Curr Pharm Des; 2004; 10(9):939-49. PubMed ID: 15078125 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of thrombin by sulfated polysaccharides isolated from green algae. Hayakawa Y; Hayashi T; Lee J; Srisomporn P; Maeda M; Ozawa T; Sakuragawa N Biochim Biophys Acta; 2000 Nov; 1543(1):86-94. PubMed ID: 11087944 [TBL] [Abstract][Full Text] [Related]
19. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Cosmi B; Cini M; Legnani C; Pancani C; Calanni F; Coccheri S Thromb Res; 2003 Mar; 109(5-6):333-9. PubMed ID: 12818259 [TBL] [Abstract][Full Text] [Related]
20. Highly sulfated dermatan sulfate from the skin of the ray Raja montagui: anticoagulant activity and mechanism of action. Ben Mansour M; Dhahri M; Hassine M; Ajzenberg N; Venisse L; Ollivier V; Chaubet F; Jandrot-Perrus M; Maaroufi RM Comp Biochem Physiol B Biochem Mol Biol; 2010 Jul; 156(3):206-15. PubMed ID: 20363356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]